Precision Medicine and ImmunotherapyResearch Advocacy Training and Support Program 

Our webinar will begin shortly.

WELCOME!

• Speaker(s): Dr. Christopher Lieu, MD University of Colorado Gastrointestinal Malignancies Program

• Archived Webinars: FightColorectalCancer.org/Webinars

• AFTER THE WEBINAR: Expect an email with links to the recording.

• Ask a question in the panel on the RIGHT SIDE of your screen

• Follow along via Twitter – use the hashtag #CRCWebinar

Today’s Webinar:

What is a RESEARCH ADVOCATE? A research advocate brings a patient viewpoint to the research process and communicates a collective patient perspective

Fight CRC’s Research Advocacy Training and Support (RATS) Program: • Goal is to improve the ability of research

advocates to effectively participate in the research process.

• In person meetings, online trainings, and webinars.

• Continued education and ongoing training and support

Brought to you by RATS:

Resources:

Disclaimer:

The information and services provided by Fight Colorectal Cancer are for general informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnoses or treatment.

If you are ill, or suspect that you are ill, see a doctor immediately. In an emergency, call 911 or go to the nearest emergency room.

Fight Colorectal Cancer never recommends or endorses any specific physicians, products or treatments for any condition.

Speaker: Chris Lieu, M.D.

Dr. Lieu is one of our hosts for the research advocacy training at the University of Colorado. Dr. Lieu joined the University of Colorado School of Medicine faculty as an Assistant Professor in July 2011.  

He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident.  He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010.

Precision Medicine and ImmunotherapyResearch Advocacy Training and

Support

Christopher Lieu, MDUniversity of Colorado

Gastrointestinal Malignancies ProgramOctober 22, 2015

Christopher Lieu, MDUniversity of ColoradoGastrointestinal Malignancies Program

Christopher Lieu, MDUniversity of ColoradoGastrointestinal Malignancies Program

Agenda• Know Your Biomarker

• Science Behind Biomarkers

• Immunotherapy

• Questions

The Science Behind Biomarkers

Show me the Data!

RAS Mutations Predict (Lack of) Benefit to EGFR Therapy

Refractory CRC RCetuximab alone

Best supportive care

Karapetis et al. NEJM 2008, 359 (17): 1757

BRAF Mutant Colon Cancer: Atypical Location of Metastases and Poor Survival

Tran, Kopetz, et al, Cancer ‘11

0%

50%

100%

150%

200%

250% BRAF wild type

P<0.05

P<0.05

P<0.05P<0.05

Incr

ease

d in

cide

nce

com

pare

d to

BR

AF

wild

type

Hazard Ratio of 10.6 for OSLess than 1 year OS

BRAF inhibition in Melanoma

BRAF Inhibition in Melanoma

Wagle et al. J Clin Oncol. 2011.

Immunotherapy

The Importance of the PD-1/PD-L1 Pathway

• Inhibiting PD-L1/PD-1 and PD-L1/B7.1 interactions can restore antitumor T-cell activity and enhance T-cell priming

• Antibodies that bind to PD-1 and PD-L1 are currently in development

• Nivolumab and pembrolizumab are currently FDA-approved

1. Akbari. Mucosal Immunol. 2010; 2. Matsumoto. Biochem Biophys Res Commun. 2008.

Mutations per tumor

Slide 12

Slide 11

Summary• Biomarker testing is becoming more common,

especially in clinical trials– Testing is usually performed by biopsy, but new

technologies are emerging (e.g. liquid biopsy)

• We are limited by what we don’t know about cancer biology– Biomarkers aren’t perfect

• Immunotherapies are emerging as effective treatment options– Currently, they do not work for all tumors

Question & Answer:

SNAP A #STRONGARMSELFIEBayer HealthCare will donate $1 for every photo posted (up to $25,000).Flex a “strong arm” & post it to Twitter or Instagram! (Use the hashtag!)